| Abstrakt: |
A study conducted by researchers at Shahed University in Tehran, Iran, explores the potential advantages of using idarubicin-loaded trastuzumab-coated liposomes for treating head and neck squamous cell carcinoma (HNSCC). HNSCC is a common type of cancer with a high mortality rate. The study found that liposomal idarubicin, a drug encapsulated in liposomes, showed higher toxicity against HNSCC cells compared to traditional free drug formulations. The immunoliposomal form of idarubicin, which was decorated with trastuzumab, was even more effective in killing HNSCC cells. The researchers also conducted simulations that suggested increased affinity between trastuzumab and HER2, a protein overexpressed in HNSCC cells. This research provides insights into potential targeted therapies for HNSCC. [Extracted from the article] |
